<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118533</article-id><article-id pub-id-type="publisher-id">ACM-44754</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_18615011.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  经皮冠状动脉介入治疗术后支架内再狭窄因素的探讨
  Discussion on the Factors of In-Stent Restenosis after Percutaneous Coronary Intervention
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>博博</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>晨霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3638</fpage><lpage>3643</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  支架内再狭窄是冠心病介入治疗中面临的重大医学题，也是研究的热点，其主要发生机制尚不清楚，可能与平滑肌过度增生，血管壁的重塑，炎症反应等有关，且其影响因素众多。现就支架内再狭窄的影响因素予以综述。
   In-stent restenosis is a major medical problem in the interventional treatment of coronary heart disease, and is also a research hotspot. Its main mechanism is still unclear, which may be related to smooth muscle hyperplasia, vascular wall remodeling, inflammatory response, etc., and its influencing factors are numerous. This article reviews the influencing factors of in-stent restenosis.
 
</p></abstract><kwd-group><kwd>冠状动脉粥样硬化性心脏病，经皮冠状动脉介入治疗，支架内再狭窄，影响因素, Coronary Atherosclerotic Heart Disease (CHD)</kwd><kwd> Percutaneous Coronary Intervention (PCI)</kwd><kwd> In-Stent Restenosis (ISR)</kwd><kwd> Influencing Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>支架内再狭窄是冠心病介入治疗中面临的重大医学题，也是研究的热点，其主要发生机制尚不清楚，可能与平滑肌过度增生，血管壁的重塑，炎症反应等有关，且其影响因素众多。现就支架内再狭窄的影响因素予以综述。</p></sec><sec id="s2"><title>关键词</title><p>冠状动脉粥样硬化性心脏病，经皮冠状动脉介入治疗，支架内再狭窄，影响因素</p></sec><sec id="s3"><title>Discussion on the Factors of In-Stent Restenosis after Percutaneous Coronary Intervention<sup> </sup></title><p>Bobo Ma, Chenxia Wang<sup>*</sup></p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/50-1572488x5_hanspub.png?20210826083316745" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 18<sup>th</sup>, 2021; published: Aug. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/50-1572488x6_hanspub.png?20210826083316745" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In-stent restenosis is a major medical problem in the interventional treatment of coronary heart disease, and is also a research hotspot. Its main mechanism is still unclear, which may be related to smooth muscle hyperplasia, vascular wall remodeling, inflammatory response, etc., and its influencing factors are numerous. This article reviews the influencing factors of in-stent restenosis.</p><p>Keywords:Coronary Atherosclerotic Heart Disease (CHD), Percutaneous Coronary Intervention (PCI), In-Stent Restenosis (ISR), Influencing Factors</p><disp-formula id="hanspub.44754-formula26"><graphic xlink:href="//html.hanspub.org/file/50-1572488x7_hanspub.png?20210826083316745"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/50-1572488x8_hanspub.png?20210826083316745" /> <img src="//html.hanspub.org/file/50-1572488x9_hanspub.png?20210826083316745" /></p></sec><sec id="s5"><title>1. 前言</title><p>随着社会经济的发展和国民生活方式的改变，心血管疾病的发病率呈上升趋势。目前，占城乡居民总死因居首位，其中农村占45.91%，城市占43.56%。心血管疾病给人们和社会带来的经济负担日益加重，在未来心血管疾病将成为全球死亡人数最多的疾病 [<xref ref-type="bibr" rid="hanspub.44754-ref1">1</xref>]。目前，中国有1100万人患有冠状动脉粥样硬化性心脏病(coronary atherosclerotic heart disease, CHD)。据世界银行估计，到2030年，中国冠心病患者将增至2263万人 [<xref ref-type="bibr" rid="hanspub.44754-ref2">2</xref>]。经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)的出现已显著降低了CHD的死亡率，提高了患者的生活质量。但支架内再狭窄(in-stent restenosis, ISR)的发生一直制约着其远期疗效。</p><p>经皮冠状动脉腔内血管成形术(Percutaneous transluminal coronary angioplasty, PTCA)再狭窄率为32%~40%。裸金属支架(Bare metal stand, BMS)通过减少弹性收缩和负性重塑的影响，降低了球囊动脉成形术观察到的再狭窄率，但再狭窄率为17%~32%。而药物洗脱支架(drug eluting stent, DES)的出现和新型抗血小板药的应用使再狭窄率显著降低，与BMS-ISR相比，DSE-ISR发生较晚，约为手术后6~12个月，且大多表现为局灶性狭窄。DSE在金属支架表面涂上抗内膜增生药物，能通过局部药释放防止支架内再狭窄，而不会导致全身毒性反应。但支架本身引起的动脉内膜损伤和增生导致的ISR问题仍未解决，再狭窄率仍在10%左右 [<xref ref-type="bibr" rid="hanspub.44754-ref3">3</xref>]。目前ISR的形成机制仍不清楚，ISR的发生和发展涉及到许多因素。早期发现ISR风险患者并密切随访可改善预后，因此有必要探讨其相关影响因素。</p></sec><sec id="s6"><title>2. 概念</title><p>ISR是指PCI术后冠状动脉造影显示支架植入节段及支架近、远端5 mm节段管腔直径狭窄50%以上，伴或不伴临床症状、不良心血管事件(死亡、MI、再次血管重建等) [<xref ref-type="bibr" rid="hanspub.44754-ref3">3</xref>]。冠状动脉造影目前是ISR诊断的金标准。临床再狭窄定义：直径大于50%的狭窄，且有以下情况之一：心绞痛复发史、缺血的客观体征(如心电图改变)、血流储备分数(FFR)小于0.80、血管内超声(IVUS)最小横截面积小于4 mm<sup>2</sup> (左主干&lt; 6 mm<sup>2</sup>)、或再狭窄(管腔直径缩小 &gt; 70%)。临床再狭窄是靶病变血运重建(TLR)的必要条件。</p></sec><sec id="s7"><title>3. 支架内再狭窄的分型</title><p>根据再狭窄的关系及其长度，ISR可分为4种类型：1) 局灶型：再狭窄位于原支架内且长度 ≤ 10 mm；2) 弥漫型：再狭窄位于原支架内且长度 &gt; 10 mm；3) 增殖型：再狭窄延伸至支架外且长度 &gt; 10 mm；4) 闭塞型：安放支架处的冠状动脉节段完全堵塞；ISR以局灶型为主 [<xref ref-type="bibr" rid="hanspub.44754-ref4">4</xref>]。</p></sec><sec id="s8"><title>4. 支架内再狭窄的影响因素</title><p>冠脉支架植入术后ISR的影响因素与以下几个方面有关：</p><sec id="s8_1"><title>4.1. 患者自身因素</title><p>ISR的发生与老年、性别差异、高血压、糖尿病尤其是胰岛素依赖型糖尿病、遗传或基因多态性、生活习惯有关。Park指出，糖尿病(diabetes mellitus, DM)是PCI术后ISR的独立危险因素。他们认为，糖尿病患者ISR的风险是普通患者的2~4倍 [<xref ref-type="bibr" rid="hanspub.44754-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.44754-ref6">6</xref>]。然而，DM病人PCI术后ISR的机制仍不清楚，可能与DM患者长期血糖、血脂和凝血系统异常，引起血管内膜增生、血液高凝、炎症因子释放过多、内皮功能障碍和其他并发症有关 [<xref ref-type="bibr" rid="hanspub.44754-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44754-ref8">8</xref>]。李隋平等的荟萃分析显示，DM患者的糖代谢异常导致胰岛素分泌不足，从而损害血管内皮细胞，从而刺激大量生长因子的产生，加速炎症细胞的增殖，促进内膜的增殖。同时，DM患者凝血功能紊乱，血小板容易粘附在受损的血管内皮上形成血栓，从而使血管腔变窄，形成ISR [<xref ref-type="bibr" rid="hanspub.44754-ref9">9</xref>]。</p><p>此外，吸烟者发生再狭窄的可能性是不吸烟者的5.916倍。烟雾中的一氧化碳和尼古丁会引起心肌组织缺氧，诱发冠脉痉挛，增加血液粘度，干扰脂质代谢，加速胆固醇的沉积，降低高密度脂蛋白，增加低密度脂蛋白胆固醇人的数量，从而降低血清的抗氧化作用，促进动脉硬化和冠心病的发生发展。美国疾病预防控制中心的一项研究显示，禁烟3年后，因心脏病住院人数下降了41% [<xref ref-type="bibr" rid="hanspub.44754-ref10">10</xref>]。戒烟使冠心病的长期死亡率降低36% [<xref ref-type="bibr" rid="hanspub.44754-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44754-ref12">12</xref>]。</p><p>在2020年的《冠心病心脏康复基层指南》中，专家一致认为，心脏康复中的药物、运动、营养、心理行为干预、戒烟限酒等综合医疗措施，大大降低急性缺血性心脏病的发生率和再住院率，且急性心肌梗死患者1年内猝死风险降低45%。心脏康复治疗可以延缓动脉粥样硬化的发展，提高生活质量，使患者尽快恢复状态，回归社会。因此，有必要对心血管疾病患者进行康复治疗 [<xref ref-type="bibr" rid="hanspub.44754-ref13">13</xref>]。</p><p>临床研究证实同型半胱氨酸(Hcy)是冠心病的独立危险因素。Hcy不仅可以损害血管内皮细胞的功能，加速动脉粥样硬化斑块的形成，还能促进血管平滑肌细胞增殖，促进动脉粥样硬化；同时增强ACE活性，减少肾小球滤过率和肾血流灌注，增加水钠重吸收，使血压升高；也损伤血小板NO和(或) NO合酶系统，使血小板功能异常易致血栓形成等 [<xref ref-type="bibr" rid="hanspub.44754-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44754-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44754-ref16">16</xref>]。</p></sec><sec id="s8_2"><title>4.2. 生物标记物</title><p>现在己知，ISR与高敏C反应蛋白、中性粒细胞等炎因子，还有脂蛋白相关碱性磷酸酶A2 (Lp-PLA2)、脂联素(ANP)、脂蛋白(a)、BNP、同型半胱氨酸和D-二聚体等有关。ISR也可能与以下生物标志物存在相关关系。</p><p>研究发现，单核细胞/高密度脂蛋白胆固醇比值(MHR)是动脉硬度指数的独立预测因子 [<xref ref-type="bibr" rid="hanspub.44754-ref17">17</xref>]。一项对468例使用裸支架治疗的稳定型或不稳型心绞痛病人的回顾性研究发现，MHR与超敏C反应蛋白和尿酸有关。此外，高MHR水平的患者支架内再狭窄的发生率较高，MHR水平升高是ISR的一个独立且有力的预测因素 [<xref ref-type="bibr" rid="hanspub.44754-ref18">18</xref>]。Tok等 [<xref ref-type="bibr" rid="hanspub.44754-ref19">19</xref>] 回顾性分析了831例在BMS接受植入治疗的稳定或不稳定心痛患者，他们得出结论，术前高MHR是该组中ISR的独立预测因素。在受试者ROC曲线分析中，MHR &gt; 14预测ISR的敏感性和特异性分别为71%和69%。</p><p>Maheronnaghsh M. [<xref ref-type="bibr" rid="hanspub.44754-ref20">20</xref>] 认为，外周血单核细胞中的微小RNA (miRNA)可能是引起再狭窄的关键病理过程的重要因子，结果显示miR-152受试者工作特征(ROC)曲线下面积(AUC)为0.717 (95%CI: 0.60~0.83)，灵敏度为70%，特异性为67%。miRNA的表达水平可用于预测CAD病患ISR的风险。这是首次证明miR-152的表达水平能用来预测CHD患者ISR的风险。miR-152在PBMC的表达水平可作为ISR的生物标志物。</p><p>C1q肿瘤坏死因子相关蛋白3 (CTRP3)与糖尿病、高血压、高血脂、冠心病等心血管疾病有关，并参与这些疾病的发生和发展 [<xref ref-type="bibr" rid="hanspub.44754-ref21">21</xref>]。2012年，孙阳等人发现，心梗后CTRP3的表达和产生显著减少，CTRP3能增加缺血区域心肌细胞的成活/再生，增强梗死边界区域的血运重建，减少细胞凋亡，减轻缺血后的病理重塑 [<xref ref-type="bibr" rid="hanspub.44754-ref22">22</xref>]。这项研究首次直接证明CTRP3具有很强的抗重塑和心脏保护作用。杨铠榕等人发现ISR患者的血清CTRP3水平显著降低，呈负相关，CTRP3 &lt; 69.49是ISR的独立危险因素 [<xref ref-type="bibr" rid="hanspub.44754-ref23">23</xref>]。</p><p>Lupi等 [<xref ref-type="bibr" rid="hanspub.44754-ref24">24</xref>] 发现，急性心梗患者中，纤维蛋白原(Fib)与支架内再狭窄呈正相关，且支架晚期管腔丢失更为严重。Fib是纤维蛋白的前身，是一种半衰期较短的血浆蛋白，除了作为凝血因子外，也是一种急性时相蛋白，调节炎性细胞黏附和迁移，促进血管平滑肌细胞血管增生和局部内膜增生，从而引起ISR。白蛋白(Alb)是一种负急性期蛋白，除了调节细胞外液中的渗透压作用外，还可通过增加前列腺素D2的产生来抑制血小板活化和凝集，从而抑制血管平滑肌细胞的迁移和增殖。同时，Alb也是重要的抗氧化剂，有效降低氧自由基对平滑肌细胞增殖和内膜增生的影响，降低再狭窄的发生率 [<xref ref-type="bibr" rid="hanspub.44754-ref25">25</xref>]。Karahan等 [<xref ref-type="bibr" rid="hanspub.44754-ref26">26</xref>] 发现纤维蛋白原与白蛋白(FAR)的比率与心肌梗死急性ST段抬高患者的冠状动脉疾病严重程度密切相关，FAR与SYNTAX评分呈正相关，患者FAR评分SYNTAX评分22分高于SYNTAX评分 &lt; 22分组。</p></sec><sec id="s8_3"><title>4.3. 支架相关因素</title><p>冠状动脉植入支架的长度和数量主要取决于病变的特点。当病变较长或位于分叉处时，通常需要选择合适的长度支架或多个短支架来覆盖病变。目前支架完全覆盖被认为是支架失败(支架血栓形成或ISR)和MACE事件的预测因素之一。支架扩张不足、贴壁不良或断裂、药物洗脱过程不均匀、两个支架之间的间隙、对抗增殖药物的生物抗性、对BMS或DES化合物的超敏反应、残余动脉粥样硬化病变和支架外气压伤，也与ISR进程有关。在多个病变间隔 &lt; 10 mm，重叠支架通常比留下短间隙好，因为间隙的存在增加了随后再狭窄的风险。支架断裂也有1%~16%的ISR病例报道，通常与局灶性ISR有关 [<xref ref-type="bibr" rid="hanspub.44754-ref27">27</xref>]。</p></sec><sec id="s8_4"><title>4.4. 冠状动脉病变因素</title><p>支架置入术后再狭窄与病变的部位、长度、程度及性质有关。Albertal [<xref ref-type="bibr" rid="hanspub.44754-ref28">28</xref>] 21例ISR分析，结果表明，左前降支占70%，回旋支占10%，右回旋支占20%。弥漫钙化性病变、多支病变、小血管病变、分叉病变、严重坏死也与支架内再狭窄有关。韩雅玲等人证实，最小管腔直径 &lt; 3.0 mm和靶病变长度15 mm是冠脉支架内再狭窄的独立危险因素。CHD患者中有心肌桥的ISR和MACE的发病率高于没有心肌桥的患者。心肌桥可能会增加ISR的发病率 [<xref ref-type="bibr" rid="hanspub.44754-ref29">29</xref>]。正性重塑是斑块进展和不稳定的标志。Sahara等研究认为正性重塑是斑块进展和不稳定的标志，可导致ISR的发生 [<xref ref-type="bibr" rid="hanspub.44754-ref30">30</xref>]。</p></sec><sec id="s8_5"><title>4.5. 其他因素</title><p>医生的不熟练操作会加重冠脉的损伤的程度。而球囊扩张、球囊本身的机械作用、扩张速度、前后扩张的压力、血管壁的伸展都会导致内皮损伤，这也是再狭窄的因素。在评价狭窄程度和是否行PCI时，通常取决于术者在造影过程中的目测判断。目测结果不仅存在操作者“变异”包括操作者内变异(intraoperator variance)和操作者间变异(interoperator variance)，而且存在判断倾向，在细小血管和严重弥漫性病变的狭窄程度判断时，由于图像质量欠佳，术者更倾向于高估病变的狭窄程度。利用定量冠脉造影(quantitative coronary angiography, QCA)分析软件进行数据处理有助于减少目测误差，再者新生内膜增生所致的管腔狭窄是一个连续的过程，采用定量指标能够动态评估ISR情况 [<xref ref-type="bibr" rid="hanspub.44754-ref31">31</xref>]。在介入治疗，手术中血管插入的时间、插入的比例和抗凝措施可能导致炎症反应。支架植入期间没有X光和血管内超声(IVUS)的指导也会增加ISR的发病率 [<xref ref-type="bibr" rid="hanspub.44754-ref32">32</xref>]。患者PCI治疗前、后的心理障碍可能影响ISR的发病率。有研究指出，长期抑郁可通过HPA轴心和五羟色胺系统等释放瘦素，瘦素的增加可激活RAAS系统引起高血压和内皮损伤。此外，病人出院后能否听从医生的建议也是ISR的一个重要环节。许红等对361例冠心病患者出院后的服药、饮食治疗、运动治疗、是否戒烟及定期复查情况进行了调查，结果97.2%患者能坚持服用阿司匹林，但服用ACEI和他汀类药的依从性较差，53.7%的患者坚持合理饮食，39.1%的患者坚持适度运动，90.9%的患者戒烟戒酒，48.7%的患者坚持复查，42.4%的患者能定期检测血压、血脂和血糖。因此，建立长期有效的干预机制，改善患者的遵医行为显得尤为重要。</p><p>目前ISR的发生机制复杂，ISR的发生也无法完全避免，影响因素众多，其相关理论有待进一步研究和厘清，为ISR的预防控制提供更多依据。在目前临床工作中，ISR的治疗主要是单纯球囊扩张术、切割球囊术、CABG术、再次支架植入术和血管内放射治疗等，但效果不佳。ISR治疗的仍是重中之重，药物涂层球囊和可生物降解支架异军突起。手术中采用新的治设备和影像学模式，大大改善了这些难治性病变的治疗和预后。例如，血管内超声波(IVUS)或光学相干断层扫描血管造影(OCT)和冠脉成像能帮助确定冠脉ISR的潜在发展机制，并可能指导最佳治疗。我相信在不久的将来，ISR的问题将得到解决，并将受益于全人类的健康。</p></sec></sec><sec id="s9"><title>文章引用</title><p>马博博,王晨霞. 经皮冠状动脉介入治疗术后支架内再狭窄因素的探讨Discussion on the Factors of In-Stent Restenosis after Percutaneous Coronary Intervention[J]. 临床医学进展, 2021, 11(08): 3638-3643. https://doi.org/10.12677/ACM.2021.118533</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44754-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">《心肺血管病杂志》编辑部. 中国心血管健康与疾病报告2019 [J]. 心肺血管病杂志, 2020, 39(9): 1145-1156.</mixed-citation></ref><ref id="hanspub.44754-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 高血压联盟(中国), 中国老年保健协会养老与健康专业委员会, 国家老年疾病临床医学研究中心中国老年心血管, 等. 基层心血管病综合管理实践指南2020 [J]. 中国医学前沿杂志(电子版), 2020, 12(8): 1, 1-73.</mixed-citation></ref><ref id="hanspub.44754-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会, 中华心血管病杂志编辑委员. 经皮冠状动脉介入治疗指南(2009) [J]. 中华心血管病杂志, 2009, 37(1): 4-25.</mixed-citation></ref><ref id="hanspub.44754-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Mehran, R., Dangas, G., Abizaid, A.S., Mintz, G.S., Lansky, A.J., Satler, L.F., et al. (1999) Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome. Circulation, 100, 1872-1878.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.100.18.1872</mixed-citation></ref><ref id="hanspub.44754-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Park, H.J., Seo, S.M., Shin, W.S., Kim, H.-Y., Choi, Y.S., Koh, Y.S., et al. (2011) Soluble Receptor for Advanced Glycation End Products Is Associated with In-Stent Restenosis in Patients with Type 2 Diabetes with Drug-Eluting Coronary Stents. Coronary Artery Disease, 22, 12-17. &lt;br&gt;https://doi.org/10.1001/jama.301.5.480</mixed-citation></ref><ref id="hanspub.44754-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Alsever, R.N., Thomas, W.M., Nevin-Woods, C., et al. (2009) Reduced Hospitalizations for Acute Myocardial Infarction after Implementation of a Smoke-Free Ordinance-City of Pueblo, Colorado, 2002-2006. JAMA, 301, 480-483.  
&lt;br&gt;https://doi.org/10.1001/jama.301.5.480</mixed-citation></ref><ref id="hanspub.44754-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yonetsu, T., Kato, K., Kim, S.J., Xing, L., Jia, H., McNulty, I., et al. (2012) Predictors for Neoatherosclerosis: A Retrospective Observational Study from the Optical Coherence Tomography Registry. Circulation: Cardiovascular Imaging, 5, 660-666. &lt;br&gt;https://doi.org/10.1161/CIRCIMAGING.112.976167</mixed-citation></ref><ref id="hanspub.44754-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Ming, T.X., Yuan, L., Chen, B., Xu, Z.R., Guo, Q.H., et al. (2016) Prevalence of Dyslipidemia and Its Control in Type 2 Diabetes: A Multicenter Study in Endocrinology Clinics of China. Journal of Clinical Lipidology, 10, 150-160. &lt;br&gt;https://doi.org/10.1016/j.jacl.2015.10.009</mixed-citation></ref><ref id="hanspub.44754-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., Luo, C. and Chen, H. (2021) Risk Factors of In-Stent Restenosis in Patients with Diabetes Mellitus after Percutaneous Coronary Intervention. Medicine, 100, e25484. &lt;br&gt;https://doi.org/10.1097/md.0000000000025484</mixed-citation></ref><ref id="hanspub.44754-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Apelberg, B.J., Onicescu, G., Avila-Tang, E. and Samet, J.M. (2010) Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States. American Journal of Public Health, 100, 341-348.  
&lt;br&gt;https://doi.org/10.2105/ajph.2008.147223</mixed-citation></ref><ref id="hanspub.44754-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hardoon, S.L., Whincup, P.H., Petersen, I., Capewell, S. and Morris, R.W. (2011) Trends in Longer-Term Survival Following an Acutemyocardial Infarction and Prescribing of Evidenced-Based Me Dications in Primary Care in the UK from 1991: A Longitudinal Population-Based Study. Journal of Epidemiology &amp; Community Health, 65, 770-774.  
&lt;br&gt;https://doi.org/10.1136/jech.2009.098087</mixed-citation></ref><ref id="hanspub.44754-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 中华医学会心血管病学分会预防学组,中华医学会心血管病学分会康复学组, 中华医学会《中华全科医师杂志》编辑委员会, 心血管系统疾病基层诊疗指南编写专家组. 冠心病心脏康复基层指南(2020年) [J].中华全科医师杂志, 2021, 20(2): 150-165.</mixed-citation></ref><ref id="hanspub.44754-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Akhabue, E., Thiboutot, J., Cheng, J.W., Vittorio, T.J., Christodoulidis, G., Grady, KM., et al. (2014) New and Emerging Risk Factors for Coronary Heart Disease. The American Journal of the Medical Sciences, 347, 151-158.</mixed-citation></ref><ref id="hanspub.44754-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">凌政, 吕海权, 陆敏, 翚崇柳, 雷敏, 谭子烈, 等. H型高血压与冠心病冠脉病变严重程度的关系研究[J]. 右江医学, 2014, 42(6): 637-640.</mixed-citation></ref><ref id="hanspub.44754-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张明玺, 罗俊. H型高血压的病因及发病机制[J]. 心血管病学进展, 2012, 33(2): 253-256．</mixed-citation></ref><ref id="hanspub.44754-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Yayla, K.G., Canpolat, U., Yayla, C., Akboğa, M.K., Akyel, A., Akdi, A., et al. (2017) A Novel Marker of Impaired Aortic Elasticity in Never Treated Hypertensive Patients: Monocyte/High-Density Lipoprotein Cholesterol Ratio. Acta Cardiologica Sinica, 33, 41-49.</mixed-citation></ref><ref id="hanspub.44754-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ucar, F.M. (2016) A Potential Marker of Bare Metal Stent Restenosis: Monocyte Count-to-HDL Cholesterol Ratio. BMC Cardiovasc Disord, 16, Article No. 186. &lt;br&gt;https://doi.org/10.1186/s12872-016-0367-3</mixed-citation></ref><ref id="hanspub.44754-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tok, D., Turak, O., Yayla, C., Ozcan, F., Tok, D. and Çağlı, K. (2016) Monocyte to HDL Ratio in Prediction of BMS Restenosis in Subjects with Stable and Unstable Angina Pectoris. Biomarkers in Medicine, 10, 853-860.  
&lt;br&gt;https://doi.org/10.2217/bmm-2016-0071</mixed-citation></ref><ref id="hanspub.44754-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Maheronnaghsh, M., Niktab, I., Enayati, S., Amoli, M.M., Hosseini, S.K. and Tavakkoly-Bazzaz J. (2021) Differentially Expressed miR-152, a Potential Biomarker for In-Stent Restenosis (ISR) in Peripheral Blood Mononuclear Cells (PBMCs) of Coronary Artery Disease (CAD) Patients. Nutrition, Metabolism &amp; Cardiovascular Diseases, 31, 1137-1147.  
&lt;br&gt;https://doi.org/10.1016/j.numecd.2020.09.030</mixed-citation></ref><ref id="hanspub.44754-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L.Y., Wu, F.F., Yuan, S.J. and Feng, B. (2016) Identification and Characteristic of Three Members of the C1q/TNF-Related Proteins (CTRPs) Superfamily in Eudontomyzonmorii. Fish &amp; Shellfish Immunology, 59, 233-240.  
&lt;br&gt;https://doi.org/10.1016/j.fsi.2016.10.034</mixed-citation></ref><ref id="hanspub.44754-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Yi, W., Sun, Y., Yuan, Y., Lau, W.B., Zheng, Q., Wang, X., et al. (2012) C1q/Tumor Necrosis Factor-Related Protein-3, a Newly Identified Adipokine, Is a Novel Antiapoptotic, Proangiogenic, and Cardioprotective Molecule in the Ischemic Mouse Heart. Circulation, 125, 3159-3169. &lt;br&gt;https://doi.org/10.1161/circulationaha.112.099937</mixed-citation></ref><ref id="hanspub.44754-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">杨铠榕. CTRP3与冠脉药物洗脱支架置入术后支架内再狭窄的相关性研究[D]: [硕士学位论文]. 延安: 延安大学, 2018.</mixed-citation></ref><ref id="hanspub.44754-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Alessandro, L., Secco, G.G., Rognoni, A., Rossi, L., Lazzero, M, Nardi, F., et al. (2012) Plasma Fibrinogen Levels and Restenosis after Primary Percutaneous Coronary Intervention. Journal of Thrombosis and Thrombolysis, 33, 308-317.  
&lt;br&gt;https://doi.org/10.1007/s11239-011-0628-z</mixed-citation></ref><ref id="hanspub.44754-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Roche, M., Rondeau, P., Singh, N.R., Tarnus, E. and Bourdon, E. (2008) The Antioxidant Properties of Serum Albumin. FEBS Letters, 582, 1783-1787. &lt;br&gt;https://doi.org/10.1016/j.febslet.2008.04.057</mixed-citation></ref><ref id="hanspub.44754-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Karahan, O., Acet, H., Ertaş, F., Tezcan, O., Çalişkan, A., Demir, M., et al. (2016) The Relationship between Fibrinogen to Albumin Ratio and Severity of Coronary Artery Disease in Patients with STEMI. The American Journal of Emergency Medicine, 34, 1037-1042. &lt;br&gt;https://doi.org/10.1016/j.ajem.2016.03.003</mixed-citation></ref><ref id="hanspub.44754-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Albertal, M., Abizaid, A., Muñoz, J.S., Mintz, G.S., Abizaid, A.S., Feres, F., et al. (2005) A Novel Mechanism Explaining Early Lumen Loss Following Balloon Angioplasty for the Treatment of In-Stent Restenosis. American Journal of Cardiology, 95, 751-754. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2004.11.028</mixed-citation></ref><ref id="hanspub.44754-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">张辉, 许官学. 心肌桥与冠状动脉内支架植入术后再狭窄的相关性研究[J]. 大家健康(学术版), 2016, 10(8): 10-11.</mixed-citation></ref><ref id="hanspub.44754-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hecht, H.S., Polena, S., Jelnin, V., Jimenez, M., Bhatti, T., Parikh, M., et al. (2009) Stent Gap by 64-Detector Computed Tomographic Angiography Relationship to In-Stent Restenosis, Fracture, and Overlap Failure. Journal of the American College of Cardiology, 54, 1949-1959. &lt;br&gt;https://doi.org/10.1016/j.jacc.2009.06.045</mixed-citation></ref><ref id="hanspub.44754-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Sahara, M., Kirigaya, H., Oikawa, Y., Yajima, J., Ogasawara, K., Satoh, H., Nagashima, K., Hara, H., Nakatsu, Y. and Aizawa, T. (2003) Arterial Remodeling Patterns before Intervention Predict Diffuse In-Stent Restenosis. Journal of the American College of Cardiology, 42, 1731-1738.</mixed-citation></ref><ref id="hanspub.44754-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Pocock, S., Lansky, A., Mehran, R., Popma, J.J., Fahy, M.P., Na, Y., et al. (2008) Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data from 11 Randomized, Controlled Trials. Journal of the American College of Cardiology, 51, 23-32. &lt;br&gt;https://doi.org/10.1016/j.jacc.2007.07.084</mixed-citation></ref><ref id="hanspub.44754-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">杨铠榕, 周静, 刘卫生. 冠状动脉粥样硬化性心脏病药物支架植入术后支架内再狭窄影响因素分析[J]. 岭南心血管病杂志, 2017, 23(4): 488-491.</mixed-citation></ref><ref id="hanspub.44754-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Omer, G., Tezcan, A.E., Tunckol, H., Emül, H.M., et al. (2005) High Serum Leptin Levels in Depressive Disorders with Atypical Features. Psychiatry and Clinical Neurosciences, 59, 736-738.  
&lt;br&gt;https://doi.org/10.1111/j.1440-1819.2005.01445.x</mixed-citation></ref></ref-list></back></article>